1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

20 Apr 2021
Admin
News Article

Ziopharm Oncology Announces First Patient Infused In Cd19 Rpm Car-T Phase I Clinical Trial Being Conducted By Joint Venture Partner Eden Biocell

Boston And Houston And Taipei, Taiwan, April 19, 2021 (Globe Newswire) -- Ziopharm Oncology, Inc. (&Ldquo;Ziopharm&Rdquo; Or The &Ldquo;Company&Rdquo;) (Nasdaq: Ziop), Announced Today That In March, The First Patient Was Infused In The Cd19-Specific Rapid Personalized Manufacturing (&Ldquo;Rpm&Rdquo;) Car-T Phase I Trial, Being Conducted By Eden Biocell, Its Joint Venture With Triarm Therapeutics.The Patient Was Treated At National Taiwan University Hospital Under The Direction Of Lead Investigator, Dr. Shang-Ju Wu.The Patient&Rsquo;S T Cells, Collected From The Patient Via Apheresis, Were Genetically Engineered Utilizing The Company&Rsquo;S Non-Viral Sleeping Beauty Transposon Transposase System And Infused Two Days After Gene Transfer.&Ldquo;We Are Excited To Be Conducting This Important Trial For This Experimental Treatment,&Rdquo; Said Dr. Jay Zhang, Chief Executive Officer Of Triarm Therapeutics.The Company And Eden Biocell Will Provide Updates Regarding The Experimental Treatment And Other Patient Data In The Second Half Of The Year At Appropriate Venue(S), Including Scientific Conferences, Publications And / Or Bespoke Events That The Company May Convene.About The Trial &Ldquo;Infusion Of Cd19-Specific Chimeric Antigen Receptor T-Cells Produced By Rapid Personalized Manufacture For Patients With Advanced Lymphoid Malignancies&Rdquo;This Is A Single Center Phase I, Open-Label Dose-Escalation Trial, For Patients With Relapsed Cd19+ Leukemias And Lymphomas. Up To 24 Patients Will Be Enrolled In This Trial. The Primary Endpoint Of The Trial Is To Evaluate The Safety And Tolerability Of Autologous Cd19-Specific T Cells Manufactured Using The Rpm Process.About Ziopharm Oncology, Inc.Ziopharm Is Developing Non-Viral And Cytokine-Driven Cell And Gene Therapies That Weaponize The Body&Rsquo;S Immune System To Treat The Millions Of People Globally Diagnosed With Cancer Each Year. With Its Multiplatform Approach, Ziopharm Is At The Forefront Of Immuno-Oncology. Ziopharm&Rsquo;S Pipeline Is Built For Commercially Scalable, Cost Effective T-Cell Receptor T-Cell Therapies Based On Its Non-Viral Sleeping Beauty Gene Transfer Platform, A Rapidly Manufactured Sleeping Beauty-Enabled Cd19-Specific Car-T Program, And A Precisely Controlled Il-12 Gene Therapy. The Company Has Clinical And Strategic Collaborations With The National Cancer Institute, The University Of Texas Md Anderson Cancer Center And Regeneron Pharmaceuticals. For More Information, Please Visit Www.Ziopharm.Com.About Eden Biocellin December 2018, Ziopharm And Triarm Therapeutics Announced The Launch Of Eden Biocell To Lead Clinical Development And Commercialization Of Ziopharm&Rsquo;S Rpm Sleeping Beauty-Generated Car-T Therapies In Greater China And Korea.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!